Semnur Pharmaceuticals, Inc.
SMNR
$9.00
-$10.00-52.63%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -37.95% | -16.87% | 112.86% | 112.86% | 80.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.00% | -55.84% | 11.69% | 11.69% | 58.12% |
| Operating Income | 10.00% | 55.84% | -11.69% | -11.69% | -58.12% |
| Income Before Tax | 10.00% | 55.84% | -11.69% | -11.69% | -58.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.00% | 55.84% | -11.69% | -11.69% | -58.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.00% | 55.84% | -11.69% | -11.69% | -58.12% |
| EBIT | 10.00% | 55.84% | -11.69% | -11.69% | -58.12% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 10.14% | 55.32% | -12.07% | -12.07% | -56.82% |
| Normalized Basic EPS | 9.30% | 55.93% | -13.89% | -13.89% | -59.26% |
| EPS Diluted | 10.14% | 55.32% | -12.07% | -12.07% | -56.82% |
| Normalized Diluted EPS | 9.30% | 55.93% | -13.89% | -13.89% | -59.26% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |